Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults age 18 years and older who have a confirmed biopsy diagnosis of FSGS.~2. Estimated glomerular filtration rate (eGFR) greater than or equal to 45 ml/min/1.73 m2. If eGFR is 30 - 45 ml/min/1.73 m2, a recent biopsy (within 12 months prior to Screening) must demonstrate \< 50% tubulointerstitial fibrosis.~3. Urine protein:creatinine ratio (UPCR) greater than 1.5 g/g at screening.~4. Treated with at least one but not more than 3 classes of immunosuppressants either alone or in combination, or has a contraindication to use of an immunosuppressant or is intolerant to an immunosuppressant per investigator judgment.~Exclusion Criteria:~1. Diagnosis of collapsing FSGS.~2. Advanced chronic changes on renal biopsy as evidenced by greater than 50% tubulointerstitial fibrosis.~3. Organ transplant.~4. History of malignancy, with the exception of basal or squamous cell carcinoma that has been treated and fully resolved for a minimum of 5 years.~5. Body mass index (BMI) greater than 45 kg/m2.~6. Subjects with a history of prior treatment with or use of interferon, lithium, pamidronate, mTOR inhibitors (eg, sirolimus), testosterone/anabolic steroids, anthracycline (eg, doxorubicin), heroin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PF-06730512 Cohort 1 (Type: EXPERIMENTAL): Subjects in cohort 1 will receive dose 1 Intravenous (IV) infusion.
- PF-06730512 Cohort 2 (Type: EXPERIMENTAL): Subjects in cohort 2 will receive dose 2 IV infusion.
- PF-06730512 Cohort 3 (optional) (Type: EXPERIMENTAL): Subjects in cohort 3 will receive dose 3 IV infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).